Activity Evaluation from Medscape Education.
WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.
- Robin L. Jones, BSc, MB BS, MRCP, MD:
Consultant Medical Oncologist; The Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom. Disclosure: Robin L. Jones, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Adaptimmune; Bayer; Eisai; Eli Lilly & Company; Immune Design; Merck; PhamaMar.
- Jean-Yves Blay, MD, PhD:
Professor of Medical Oncology; Centre Leon Berard, Lyon, France. Disclosure: Jean-Yves Blay, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Novartis; PharmaMar; Roche.
- Bernd Kasper, MD, PhD:
Professor of Medical Oncology; Mannheim University Medical Center, Mannheim, Germany. Disclosure: Bernd Kasper, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Bayer; Clinigen; Eisai; Eli Lilly & Company. Served as a speaker or a member of a speakers bureau for: Eisai; Eli Lilly & Company; Novartis; PharmaMar.
Editor
Content Reviewer
- Robert Morris, PharmD: Associate CME Clinical Director.Disclosure: Robert Morris, PharmD, has disclosed no relevant financial relationships.
Activity Web Page: http://www.medscape.org/viewarticle/869772
Course Material: Video // Powerpoint.
Certificate:
Dr Enrique Vicente Greco - Médico 